Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience
BACKGROUND: Currently, about 50% of diffuse large B-cell lymphoma patients are relapsed following their complete response to first-line therapy. The treatment strategy for fit patients with relapsed refractory diffuse large B-cell lymphoma (R/R DLBCL) has been done with salvage therapy with non-cros...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Iraqi Journal of Hematology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijh.ijh_62_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841551983087976448 |
|---|---|
| author | Fawaz Salim Yousif Bassam Francis Matti Zina Ali Al-Bakri Safa A. Faraj Mazin A. Mohammed Zahraa S. Shakir Mahmood W. Khalid Saba H. Al Hlali Sarah M. Saeb Kareem K. Khanjar Maryam R. Humadi |
| author_facet | Fawaz Salim Yousif Bassam Francis Matti Zina Ali Al-Bakri Safa A. Faraj Mazin A. Mohammed Zahraa S. Shakir Mahmood W. Khalid Saba H. Al Hlali Sarah M. Saeb Kareem K. Khanjar Maryam R. Humadi |
| author_sort | Fawaz Salim Yousif |
| collection | DOAJ |
| description | BACKGROUND:
Currently, about 50% of diffuse large B-cell lymphoma patients are relapsed following their complete response to first-line therapy. The treatment strategy for fit patients with relapsed refractory diffuse large B-cell lymphoma (R/R DLBCL) has been done with salvage therapy with non-cross resistant combination chemo-immunotherapy regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT).
OBJECTIVES:
The aim of study was to evaluate the outcome of ASCT for R/R DLBCL in relation to certain prognostic parameters.
PATIENTS, MATERIALS AND METHODS:
This is retrospective study, conducted from May 2014 to December 2022, at Hematology and BMT Center of Medical City Complex in Baghdad. Thirty-six patients with R/R DLBCL were investigated pre- and post-ASCT; the recorded data included patient disease status pre-transplant, early mortality rate, and type of response at day 100 post-transplant and, survival rate, relapsed rate, and mortality at the end of the study were documented accordingly.
RESULTS:
The mean age of DLBCL patients in this study was 41.3 (14–65) years, post-ASCT at day 100; there were 33 (91.6%), 2 (5.5%), and 1 (2.7%) patients in complete remission, relapsed progressive disease, and death, respectively, At 3-year posttransplant, the overall survival (OS) was 71%, whereas the event-free survival (EFS) was 59%. According to disease status pre-ASCT, the OS was 62%, 80%, and 66% with P = 0.7, whereas the EFS was 66%, 60%, and 50% with P = 0.5 for CR, UCR, and PR, respectively.
CONCLUSION:
Iraqi bone marrow transplant center data showed acceptable OS and EFS results in the treatment of R/R DLBCL patients in areas where there is no more option in terms of better OS and EFS but with insignificant relation to the available prognostic factor. |
| format | Article |
| id | doaj-art-52d1cca6d9684288807028c017d8f302 |
| institution | Kabale University |
| issn | 2072-8069 2543-2702 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Iraqi Journal of Hematology |
| spelling | doaj-art-52d1cca6d9684288807028c017d8f3022025-01-09T13:54:36ZengWolters Kluwer Medknow PublicationsIraqi Journal of Hematology2072-80692543-27022024-12-0113228228810.4103/ijh.ijh_62_24Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experienceFawaz Salim YousifBassam Francis MattiZina Ali Al-BakriSafa A. FarajMazin A. MohammedZahraa S. ShakirMahmood W. KhalidSaba H. Al HlaliSarah M. SaebKareem K. KhanjarMaryam R. HumadiBACKGROUND: Currently, about 50% of diffuse large B-cell lymphoma patients are relapsed following their complete response to first-line therapy. The treatment strategy for fit patients with relapsed refractory diffuse large B-cell lymphoma (R/R DLBCL) has been done with salvage therapy with non-cross resistant combination chemo-immunotherapy regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT). OBJECTIVES: The aim of study was to evaluate the outcome of ASCT for R/R DLBCL in relation to certain prognostic parameters. PATIENTS, MATERIALS AND METHODS: This is retrospective study, conducted from May 2014 to December 2022, at Hematology and BMT Center of Medical City Complex in Baghdad. Thirty-six patients with R/R DLBCL were investigated pre- and post-ASCT; the recorded data included patient disease status pre-transplant, early mortality rate, and type of response at day 100 post-transplant and, survival rate, relapsed rate, and mortality at the end of the study were documented accordingly. RESULTS: The mean age of DLBCL patients in this study was 41.3 (14–65) years, post-ASCT at day 100; there were 33 (91.6%), 2 (5.5%), and 1 (2.7%) patients in complete remission, relapsed progressive disease, and death, respectively, At 3-year posttransplant, the overall survival (OS) was 71%, whereas the event-free survival (EFS) was 59%. According to disease status pre-ASCT, the OS was 62%, 80%, and 66% with P = 0.7, whereas the EFS was 66%, 60%, and 50% with P = 0.5 for CR, UCR, and PR, respectively. CONCLUSION: Iraqi bone marrow transplant center data showed acceptable OS and EFS results in the treatment of R/R DLBCL patients in areas where there is no more option in terms of better OS and EFS but with insignificant relation to the available prognostic factor.https://journals.lww.com/10.4103/ijh.ijh_62_24autologous bone marrow transplantprognostic factorrelapsed and refractory diffuse large b-cell lymphoma |
| spellingShingle | Fawaz Salim Yousif Bassam Francis Matti Zina Ali Al-Bakri Safa A. Faraj Mazin A. Mohammed Zahraa S. Shakir Mahmood W. Khalid Saba H. Al Hlali Sarah M. Saeb Kareem K. Khanjar Maryam R. Humadi Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience Iraqi Journal of Hematology autologous bone marrow transplant prognostic factor relapsed and refractory diffuse large b-cell lymphoma |
| title | Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience |
| title_full | Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience |
| title_fullStr | Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience |
| title_full_unstemmed | Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience |
| title_short | Outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large B-cell lymphoma in relation with prognostic factor: A single-center experience |
| title_sort | outcome of autologous bone marrow transplant in patients with relapsed and refractory diffuse large b cell lymphoma in relation with prognostic factor a single center experience |
| topic | autologous bone marrow transplant prognostic factor relapsed and refractory diffuse large b-cell lymphoma |
| url | https://journals.lww.com/10.4103/ijh.ijh_62_24 |
| work_keys_str_mv | AT fawazsalimyousif outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT bassamfrancismatti outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT zinaalialbakri outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT safaafaraj outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT mazinamohammed outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT zahraasshakir outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT mahmoodwkhalid outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT sabahalhlali outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT sarahmsaeb outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT kareemkkhanjar outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience AT maryamrhumadi outcomeofautologousbonemarrowtransplantinpatientswithrelapsedandrefractorydiffuselargebcelllymphomainrelationwithprognosticfactorasinglecenterexperience |